Literature DB >> 9453496

Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension.

D C Rockey1, J J Chung.   

Abstract

BACKGROUND & AIMS: Intrahepatic vascular resistance is regulated in part by the vasoconstricting and relaxing effects of compounds such as endothelin and nitric oxide (NO). Although the hepatic endothelium is likely to be a prominent source of NO via production by endothelial cell NO synthase (ecNOS), this isoform has not been described in sinusoidal endothelial cells (SECs). The aim of this study was to determine whether ecNOS is produced by SECs, and, if so, to determine whether ecNOS- (mRNA/protein) or SEC-dependent production of NO varies after liver injury.
METHODS: A cDNA encoding a 279-bp fragment homologous to bovine ecNOS was isolated and used to detect rat ecNOS mRNA. Liver injury and/or cirrhosis was induced by bile duct ligation or administration of CCl4. NOS activity was quantitated and the presence of NO was detected with highly sensitive nitrite and cGMP assays.
RESULTS: ecNOS mRNA and protein (detected by immunoblot) were present only in SECs. Neither ecNOS mRNA abundance nor protein levels varied after liver injury induced by bile duct ligation or repeated CCl4 administration, including in animals with cirrhosis. Because inducible NOS is induced after bile duct ligation but not after CCl4-induced cirrhosis, we examined NOS activity and nitrite- and NO-dependent cGMP production after the latter form of injury. NOS activity and nitrite and cGMP production were significantly reduced in SECs from cirrhotic animals compared with controls (P < 0.05, n = 4-6).
CONCLUSIONS: SECs are an important source of ecNOS in the liver; although ecNOS mRNA and protein levels in SECs do not seem to vary with liver injury, ecNOS function is altered, resulting in diminished NO release in SECs from cirrhotic livers. These data have important implications for the pathogenesis of intrahepatic portal hypertension as well as other disorders in which endothelia may be damaged.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9453496     DOI: 10.1016/s0016-5085(98)70487-1

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  82 in total

Review 1.  Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension.

Authors:  H Reynaert; M G Thompson; T Thomas; A Geerts
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

2.  Fabrication and characterization of an inorganic gold and silica nanoparticle mediated drug delivery system for nitric oxide.

Authors:  Amitava Das; Priyabrata Mukherjee; Sumit K Singla; Praveen Guturu; Megan C Frost; Debabrata Mukhopadhyay; Vijay H Shah; Chitta Ranjan Patra
Journal:  Nanotechnology       Date:  2010-07-08       Impact factor: 3.874

3.  Physiopathology of splanchnic vasodilation in portal hypertension.

Authors:  María Martell; Mar Coll; Nahia Ezkurdia; Imma Raurell; Joan Genescà
Journal:  World J Hepatol       Date:  2010-06-27

4.  NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension.

Authors:  S Fiorucci; E Antonelli; O Morelli; A Mencarelli; A Casini; T Mello; B Palazzetti; D Tallet; P del Soldato; A Morelli
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

5.  Effects of neuronal nitric oxide synthase inhibition on resting and exercising hindlimb muscle blood flow in the rat.

Authors:  Steven W Copp; Daniel M Hirai; Peter J Schwagerl; Timothy I Musch; David C Poole
Journal:  J Physiol       Date:  2010-02-22       Impact factor: 5.182

6.  Effects of nitric oxide inhibition by methylene blue in cirrhotic patients with ascites.

Authors:  Georgios Kalambokis; Michalis Economou; Andreas Fotopoulos; Jihad Al Bokharhii; Pappas Christos; Kosta Paraskevi; Papadimitriou Konstantinos; Afroditi Katsaraki; Epameinondas V Tsianos
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

7.  An endothelin A receptor antagonist induces dilatation of sinusoidal endothelial fenestrae: implications for endothelin-1 in hepatic microcirculation.

Authors:  Norihito Watanabe; Shinji Takashimizu; Yasuhiro Nishizaki; Seiichiro Kojima; Tatehiro Kagawa; Shohei Matsuzaki
Journal:  J Gastroenterol       Date:  2007-09-25       Impact factor: 7.527

8.  Hemodynamic and antifibrotic effects of a selective liver nitric oxide donor V-PYRRO/NO in bile duct ligated rats.

Authors:  Frédéric Moal; Nary Veal; Eric Vuillemin; Eric Barrière; Jianhua Wang; Lionel Fizanne; Frédéric Oberti; Olivier Douay; Yves Gallois; Dominique Bonnefont-Rousselot; Marie Christine Rousselet; Paul Calès
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

9.  Endothelin antagonism in portal hypertensive mice: implications for endothelin receptor-specific signaling in liver disease.

Authors:  Hong-Qiang Feng; Nate D Weymouth; Don C Rockey
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-03-19       Impact factor: 4.052

10.  In vivo gene transfer of endothelial nitric oxide synthase decreases portal pressure in anaesthetised carbon tetrachloride cirrhotic rats.

Authors:  M Van de Casteele; A Omasta; S Janssens; T Roskams; V Desmet; F Nevens; J Fevery
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.